<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02352077</url>
  </required_header>
  <id_info>
    <org_study_id>CAS-XDA-SCI/IGDB</org_study_id>
    <nct_id>NCT02352077</nct_id>
  </id_info>
  <brief_title>NeuroRegen Scaffold™ With Stem Cells for Chronic Spinal Cord Injury Repair</brief_title>
  <official_title>Safety and Efficacy of NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells or Mesenchymal Stem Cells for Chronic Spinal Cord Injury Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Hospital of Logistics University of CAPF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospitals affiliated to the China PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of NeuroRegen scaffold with
      bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) in patients with
      chronic spinal cord injury.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Evaluation Number of patients with adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of patients with adverse events is as a measure of safety and tolerability after collagen scaffold with MSCs transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvements in Neurophysiological Measures omatosensory Evoked Potentials (SSEP) and Motor Evoked Potentials (MEP) monitoring will be assessed</measure>
    <time_frame>12 months</time_frame>
    <description>Somatosensory Evoked Potentials (SSEP) and Motor Evoked Potentials (MEP) monitoring will be assessed before and after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements in ASIA Impairment Scale</measure>
    <time_frame>12 months</time_frame>
    <description>American Spinal Injury Assessment Scale of A, B, C, D or E will be assessed before and after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements in Independence Measures and Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <description>Functional Independence Measure (FIM) and the Quality of Life Questionnaire (EQ 5D) will be assessed before and after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements in Pain assessed based on Visual analog scale (VAS)</measure>
    <time_frame>12 months</time_frame>
    <description>Pain intensity will be assessed based on Visual analog scale (VAS) before and after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvements in Urinary and Bowel Function assessed based on bladder pressure monitory before and after transplantation</measure>
    <time_frame>12 months</time_frame>
    <description>The ability to feel and control urination and bowel will be assessed based on bladder pressure monitory before and after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes at the Transplantation Site in Spinal Cord by Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>12 months</time_frame>
    <description>The MRI at the transplantation site will be assessed before and after transplantation.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>NeuroRegen Scaffold with BMMCs or MSCs transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NeuroRegen scaffold with BMMCs or MSCs transplantation</intervention_name>
    <description>Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.</description>
    <arm_group_label>NeuroRegen Scaffold with BMMCs or MSCs transplantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female, 18-65 years old.

          2. Completely spinal cord injury at the cervical and thoracic level (C5-T12).

          3. Classification ASIA A with no significant further improvement.

          4. Patients signed informed consent.

          5. Ability and willingness to regular visit to hospital and follow up during the protocol
             Procedures.

        Exclusion Criteria:

          1. A current diagnosis of any primary diseases affecting limb functions (e.g., trauma,
             infection, tumors, congenital malformations, peripheral muscular dystrophy,
             Huntington's disease, Parkinson's disease).

          2. Serious complications (e.g., hydronephrosis due to renal insufficiency, severe
             bedsores (Ⅲ° above), lower extremity venous thrombosis, severe myositis ossificans).

          3. History of life threatening allergic or immune-mediated reaction.

          4. Clinically significant abnormalities in routine laboratory examinations (hematology,
             electrolytes, biochemistry, liver and kidney function tests, urinanalysis).

          5. History of mental illness or suicide risk, with a history of epilepsy or other central
             nervous system disorders.

          6. Severe arrhythmias (e.g., ventricular tachycardia, frequent superventricular
             tachycardia, atrial fibrillation, and atrial flutter) or cardiac degree II or above
             conduction abnormalities displayed via 12-lead ECG.

          7. Lactating and pregnant woman.

          8. Alcohol drug abuse /dependence.

          9. Participated in any other clinical trials within 3 months before the enrollment.

         10. A drug or treatment known to cause effect on the central nervous system during the
             past four weeks.

         11. A drug or treatment known to cause major organ system toxicity during the past four
             weeks.

         12. Poor compliance, difficult to complete the study.

         13. Any other conditions that might increase the risk of subjects or interfere with the
             clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianwu Dai, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sai Zhang, M.D</last_name>
    <role>Study Chair</role>
    <affiliation>Affiliated Hospital of Logistics Universtiy of CAPF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huilin Yang, Ph.D</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shuxun Hou</last_name>
    <role>Study Chair</role>
    <affiliation>First Hospitals affiliated to the China PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>First Hospitals affiliated to the China PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Soochow</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Logistics Universtiy of CAPF</name>
      <address>
        <city>Tianjin</city>
        <zip>300162</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2015</study_first_posted>
  <last_update_submitted>January 1, 2018</last_update_submitted>
  <last_update_submitted_qc>January 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Jianwu Dai</investigator_full_name>
    <investigator_title>Principal Investigator of Regenerative Medicine Laboratory, Institute of Genetics and Developmental Biology, CAS</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

